"Cytokine storm", not only in COVID-19 patients. Mini-review.
Cytokine release syndrome
Cytokine storm
Treatment
Journal
Immunology letters
ISSN: 1879-0542
Titre abrégé: Immunol Lett
Pays: Netherlands
ID NLM: 7910006
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
08
07
2020
revised:
10
09
2020
accepted:
22
09
2020
pubmed:
3
10
2020
medline:
23
12
2020
entrez:
2
10
2020
Statut:
ppublish
Résumé
Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient's death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inflammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.
Identifiants
pubmed: 33007369
pii: S0165-2478(20)30386-2
doi: 10.1016/j.imlet.2020.09.007
pmc: PMC7524442
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
38-44Informations de copyright
Copyright © 2020 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.
Références
J Clin Invest. 1996 Dec 15;98(12):2819-26
pubmed: 8981930
Nihon Geka Gakkai Zasshi. 1996 Dec;97(12):1054-9
pubmed: 9032781
Immunol Lett. 2016 Jan;169:8-14
pubmed: 26602157
Blood. 2015 Dec 10;126(24):2646-9
pubmed: 26447188
Annu Rev Med. 2015;66:145-59
pubmed: 25386930
Lancet Haematol. 2019 Dec;6(12):e630-e637
pubmed: 31537486
J Allergy Clin Immunol Pract. 2017 May - Jun;5(3):600-609
pubmed: 28110056
Mediators Inflamm. 2001 Apr;10(2):51-9
pubmed: 11405550
Influenza Other Respir Viruses. 2016 Jan;10(1):57-66
pubmed: 26176755
Front Immunol. 2013 Oct 31;4:351
pubmed: 24198817
Clin Exp Immunol. 1975 Feb;19(2):387-91
pubmed: 765011
Cell Mol Immunol. 2016 Jan;13(1):3-10
pubmed: 26189369
Clin Exp Immunol. 2010 Dec;162(3):516-27
pubmed: 20964641
Am J Clin Nutr. 2018 Oct 1;108(4):857-867
pubmed: 30239561
Molecules. 2020 Apr 29;25(9):
pubmed: 32365556
Haematologica. 2014 Sep;99(9):1433-40
pubmed: 24907357
Blood. 2016 Mar 31;127(13):1666-75
pubmed: 26825707
Blood Adv. 2020 Apr 28;4(8):1656-1669
pubmed: 32324888
Br J Haematol. 2020 Aug;190(3):e150-e154
pubmed: 32584416
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Herz. 2020 Jun;45(4):335-346
pubmed: 30128908
Hemasphere. 2019 Mar 29;3(2):e191
pubmed: 31723828
Eur J Haematol. 2015 Jun;94(6):554-7
pubmed: 24913471
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
J Appl Physiol (1985). 2009 Mar;106(3):988-95
pubmed: 18845776
Pharmacol Toxicol. 2003 Apr;92(4):173-9
pubmed: 12753420
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
Biochem Pharmacol. 2010 Feb 1;79(3):413-20
pubmed: 19732754
Ecancermedicalscience. 2020 Mar 27;14:1022
pubmed: 32256705
Eurasian J Med. 2013 Oct;45(3):167-75
pubmed: 25610275
Drug Des Devel Ther. 2015 Sep 16;9:5237-46
pubmed: 26396497
Clin Vaccine Immunol. 2013 Mar;20(3):319-27
pubmed: 23283640
J Pediatr Hematol Oncol. 2016 Jan;38(1):e29-31
pubmed: 26583621
Clin Lab Med. 2008 Sep;28(3):469-79, vii-viii
pubmed: 19028264
J Crit Care. 2019 Feb;49:172-178
pubmed: 30448517
Bone Marrow Transplant. 2002 Sep;30(6):347-54
pubmed: 12235518
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Biol Blood Marrow Transplant. 2019 Jan;25(1):26-33
pubmed: 30266675
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Pharmacol Rev. 2003 Jun;55(2):241-69
pubmed: 12773629
N Engl J Med. 1989 May 25;320(21):1420-1
pubmed: 2785642
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Immunotargets Ther. 2019 Oct 29;8:43-52
pubmed: 31754614
Leuk Lymphoma. 2014 Jul;55(7):1691-3
pubmed: 24138307
Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):370-376
pubmed: 30048251
Expert Rev Anti Infect Ther. 2011 Jul;9(7):807-22
pubmed: 21810053
Clin Exp Immunol. 2003 Oct;134(1):57-62
pubmed: 12974755
J Biol Regul Homeost Agents. 2002 Apr-Jun;16(2):105-9
pubmed: 12144121
Eur J Clin Pharmacol. 2012 May;68(5):479-503
pubmed: 22105373
Ann Rheum Dis. 2018 Jun;77(6):840-847
pubmed: 29472362
Immunotherapy. 2018 Aug;10(11):913-917
pubmed: 30149764
Pediatr Clin North Am. 2012 Apr;59(2):329-44
pubmed: 22560573